Losartan v placebo for type 2 diabetes and nephropathy at 3.4 years†

OutcomesLosartanPlaceboRRR (95% CI)‡
†Abbreviations defined in glossary. ‡Based on Cox regression model. §Composite outcome = doubling of baseline serum creatinine level, end-stage renal disease, or death.
Composite outcome§44%47%16% (2 to 28)
Doubling of serum creatinine level22%26%25% (8 to 39)
End-stage renal disease20%26%28% (11 to 42)